Cargando…

No Difference in Antibody Responses to Tetanus Vaccine Among HIV-Exposed and -Unexposed Infants in Botswana

BACKGROUND: In Botswana, more than 10% of HIV-exposed, uninfected infants (HEU) are hospitalized or die in the first 6 months of life, largely due to infectious causes. Vaccine responses can act as a marker of the immune response to infectious antigens. Previous studies of antibody responses to vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Christiana, Moraka, Natasha, Ibrahim, Maryanne, Moyo, Sikhulile, Mayondi, Gloria, Kammerer, Betsy, Leidner, Jean, Gaseitsiwe, Simani, Lockman, Shahin, Weinberg, Adriana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631389/
http://dx.doi.org/10.1093/ofid/ofx163.1774
_version_ 1783269456765517824
author Smith, Christiana
Moraka, Natasha
Ibrahim, Maryanne
Moyo, Sikhulile
Mayondi, Gloria
Kammerer, Betsy
Leidner, Jean
Gaseitsiwe, Simani
Lockman, Shahin
Weinberg, Adriana
author_facet Smith, Christiana
Moraka, Natasha
Ibrahim, Maryanne
Moyo, Sikhulile
Mayondi, Gloria
Kammerer, Betsy
Leidner, Jean
Gaseitsiwe, Simani
Lockman, Shahin
Weinberg, Adriana
author_sort Smith, Christiana
collection PubMed
description BACKGROUND: In Botswana, more than 10% of HIV-exposed, uninfected infants (HEU) are hospitalized or die in the first 6 months of life, largely due to infectious causes. Vaccine responses can act as a marker of the immune response to infectious antigens. Previous studies of antibody responses to vaccines in HEU have had conflicting results. We compared antibody titers to tetanus vaccine between HEU and HIV-unexposed infants (HUU), and explored whether tetanus antibody titers predicted risk of hospitalization in the first 2 years of life among HEU. METHODS: 443 HIV-infected and 451 HIV-uninfected mothers and their 453 HEU / 457 HUU live-born infants were followed in a prospective observational study in Botswana (“Tshipidi”). Quantitative tetanus toxoid IgG was measured in plasma samples from 18-month-old infants. Geometric mean antibody titers (GMT) were compared between HEU and HUU infants, and between HEU infants who were or were not hospitalized by age 2. RESULTS: Plasma was available at 18 months for 39 HEU and 42 HUU infants. Within this subset, there were 15 hospitalizations (12 in HEU) [RR of hospitalization among HEU = 1.34 (P = 0.009)]. 73% of hospitalizations overall, and 83% in HEU, were due to infection (primarily pneumonia/bronchiolitis and gastroenteritis). Among infants who had received 3 or 4 doses of tetanus vaccine by 18 months, there were no significant differences in tetanus GMT between HEU and HUU (Fig A). Among HEU who had received 3 or 4 doses of tetanus vaccine by 18 months, there were no significant differences in tetanus GMT between infants who were hospitalized and infants who were not (Fig B). CONCLUSION: In this small sample of infants from Botswana, we did not identify differences in antibody responses to tetanus vaccine between HEU and HUU. Although HEU demonstrated an increased risk of hospitalization, response to tetanus vaccine did not appear to be a significant predictor of morbidity. It is possible that cell-mediated immune defects play a larger role than humoral immune defects in the increased susceptibility to infection among HEU. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-5631389
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-56313892017-11-07 No Difference in Antibody Responses to Tetanus Vaccine Among HIV-Exposed and -Unexposed Infants in Botswana Smith, Christiana Moraka, Natasha Ibrahim, Maryanne Moyo, Sikhulile Mayondi, Gloria Kammerer, Betsy Leidner, Jean Gaseitsiwe, Simani Lockman, Shahin Weinberg, Adriana Open Forum Infect Dis Abstracts BACKGROUND: In Botswana, more than 10% of HIV-exposed, uninfected infants (HEU) are hospitalized or die in the first 6 months of life, largely due to infectious causes. Vaccine responses can act as a marker of the immune response to infectious antigens. Previous studies of antibody responses to vaccines in HEU have had conflicting results. We compared antibody titers to tetanus vaccine between HEU and HIV-unexposed infants (HUU), and explored whether tetanus antibody titers predicted risk of hospitalization in the first 2 years of life among HEU. METHODS: 443 HIV-infected and 451 HIV-uninfected mothers and their 453 HEU / 457 HUU live-born infants were followed in a prospective observational study in Botswana (“Tshipidi”). Quantitative tetanus toxoid IgG was measured in plasma samples from 18-month-old infants. Geometric mean antibody titers (GMT) were compared between HEU and HUU infants, and between HEU infants who were or were not hospitalized by age 2. RESULTS: Plasma was available at 18 months for 39 HEU and 42 HUU infants. Within this subset, there were 15 hospitalizations (12 in HEU) [RR of hospitalization among HEU = 1.34 (P = 0.009)]. 73% of hospitalizations overall, and 83% in HEU, were due to infection (primarily pneumonia/bronchiolitis and gastroenteritis). Among infants who had received 3 or 4 doses of tetanus vaccine by 18 months, there were no significant differences in tetanus GMT between HEU and HUU (Fig A). Among HEU who had received 3 or 4 doses of tetanus vaccine by 18 months, there were no significant differences in tetanus GMT between infants who were hospitalized and infants who were not (Fig B). CONCLUSION: In this small sample of infants from Botswana, we did not identify differences in antibody responses to tetanus vaccine between HEU and HUU. Although HEU demonstrated an increased risk of hospitalization, response to tetanus vaccine did not appear to be a significant predictor of morbidity. It is possible that cell-mediated immune defects play a larger role than humoral immune defects in the increased susceptibility to infection among HEU. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2017-10-04 /pmc/articles/PMC5631389/ http://dx.doi.org/10.1093/ofid/ofx163.1774 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Smith, Christiana
Moraka, Natasha
Ibrahim, Maryanne
Moyo, Sikhulile
Mayondi, Gloria
Kammerer, Betsy
Leidner, Jean
Gaseitsiwe, Simani
Lockman, Shahin
Weinberg, Adriana
No Difference in Antibody Responses to Tetanus Vaccine Among HIV-Exposed and -Unexposed Infants in Botswana
title No Difference in Antibody Responses to Tetanus Vaccine Among HIV-Exposed and -Unexposed Infants in Botswana
title_full No Difference in Antibody Responses to Tetanus Vaccine Among HIV-Exposed and -Unexposed Infants in Botswana
title_fullStr No Difference in Antibody Responses to Tetanus Vaccine Among HIV-Exposed and -Unexposed Infants in Botswana
title_full_unstemmed No Difference in Antibody Responses to Tetanus Vaccine Among HIV-Exposed and -Unexposed Infants in Botswana
title_short No Difference in Antibody Responses to Tetanus Vaccine Among HIV-Exposed and -Unexposed Infants in Botswana
title_sort no difference in antibody responses to tetanus vaccine among hiv-exposed and -unexposed infants in botswana
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631389/
http://dx.doi.org/10.1093/ofid/ofx163.1774
work_keys_str_mv AT smithchristiana nodifferenceinantibodyresponsestotetanusvaccineamonghivexposedandunexposedinfantsinbotswana
AT morakanatasha nodifferenceinantibodyresponsestotetanusvaccineamonghivexposedandunexposedinfantsinbotswana
AT ibrahimmaryanne nodifferenceinantibodyresponsestotetanusvaccineamonghivexposedandunexposedinfantsinbotswana
AT moyosikhulile nodifferenceinantibodyresponsestotetanusvaccineamonghivexposedandunexposedinfantsinbotswana
AT mayondigloria nodifferenceinantibodyresponsestotetanusvaccineamonghivexposedandunexposedinfantsinbotswana
AT kammererbetsy nodifferenceinantibodyresponsestotetanusvaccineamonghivexposedandunexposedinfantsinbotswana
AT leidnerjean nodifferenceinantibodyresponsestotetanusvaccineamonghivexposedandunexposedinfantsinbotswana
AT gaseitsiwesimani nodifferenceinantibodyresponsestotetanusvaccineamonghivexposedandunexposedinfantsinbotswana
AT lockmanshahin nodifferenceinantibodyresponsestotetanusvaccineamonghivexposedandunexposedinfantsinbotswana
AT weinbergadriana nodifferenceinantibodyresponsestotetanusvaccineamonghivexposedandunexposedinfantsinbotswana